JPRN-jRCT1080224684已完成Unknown
TR study of A basket trial of DS-8201a, a novel HER2-targeted antibody-drug conjugate, for HER2 amplified solid tumors identified by ctDNA analysis
ational Cancer Center Hospital East0 个研究点目标入组 65 人开始时间: 2019年5月16日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Enrolled in HERALD trial.
- •2.Informed consent for participation in the HERALD TR study is obtained at the discretion of the patient.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
HERALD StudyJPRN-jRCT2080224635Aichi Cancer Center Hospital60
进行中（未招募）
1 期
未命名试验Adult patients with advanced breast cancer after at least a first line of chemotherapy in metastatic setting:-if HER2 IHC3+ or IHC2+/ISH+ resistant to trastuzumab and TDM-1-if HER2 IHC0+ or IHC1+ or IHC2+/ISH- HR+ resistant to endocrine therapy.MedDRA version: 20.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2018-004868-57-FRICANCER162
已完成
1 期
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive CancersMalignant Solid TumorMetastatic EphA2 Positive CancerNCT02252211Ludwig Institute for Cancer Research9
已完成
2 期
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisBreast TumorsNCT04132960UNICANCER186
未知
1 期
Phase I Clinical Trial of DS-7423JPRN-jRCT2080221724DAIICHISANKYO Co.,Ltd.27